Clouqueur E, Coulon C, Vaast P, Chauvet A, Deruelle P, Subtil D, Houfflin-Debarge V
Clinique d'obstétrique, pôle « femme-mère-nouveau-né », hôpital Jeanne-de-Flandre, CHRU de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France.
Clinique d'obstétrique, pôle « femme-mère-nouveau-né », hôpital Jeanne-de-Flandre, CHRU de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France.
J Gynecol Obstet Biol Reprod (Paris). 2014 Feb;43(2):146-61. doi: 10.1016/j.jgyn.2013.11.008. Epub 2014 Jan 22.
Study, based on the literature, of the use of misoprostol for induction of labor in cases of second or third trimester fetal death or termination of pregnancy and define the different mode of administration.
Bibliographic review using the Medline and Pubmed databases and the guidelines of the international professional societies. Selection of papers in French and English. Keywords used: misoprostol, termination of pregnancy, mid and third trimester, scarred uterus, previous cesarean section, uterine rupture.
Misoprostol is effective for induction of labor in case of second or third fetal death or termination of pregnancy. Comparing to oral route, vaginal route reduces the induction-expulsion time and the rate of patients remaining undelivered in the first 24 hours without increasing side effects. Oral route is a possible alternative if preferred by the patient. Sublingual route seems interesting but data are limited. The use of moderate doses (800-2400 μg/day) every 3 to 6 hours seems to be the best compromise between efficiency and tolerance. It is not possible to recommend a specific dosing schedule. The risk of uterine rupture in case of previous cesarean section justifies the use of minimum effective dose for these patients. In this case, it is recommended not to exceed a dose of 100 μg for each dose. The induction-birth period and doses of misoprostol required to induce labor are reduced when combined with mifepristone administered 36 to 48 hours before.
Misoprostol is effective and safe for induction of labor in case of second or third trimester fetal death or termination of pregnancy.
基于文献研究米索前列醇在孕中期或孕晚期胎儿死亡或终止妊娠病例中引产的应用,并确定不同的给药方式。
使用Medline和Pubmed数据库以及国际专业学会的指南进行文献综述。选择法语和英语的论文。使用的关键词:米索前列醇、终止妊娠、孕中期和孕晚期、瘢痕子宫、既往剖宫产史、子宫破裂。
米索前列醇在孕中期或孕晚期胎儿死亡或终止妊娠时引产有效。与口服途径相比,阴道途径可缩短引产-分娩时间,降低24小时内未分娩患者的比例,且不增加副作用。如果患者偏好,口服途径是一种可行的替代方法。舌下途径似乎有意义,但数据有限。每3至6小时使用中等剂量(800 - 2400μg/天)似乎是疗效和耐受性之间的最佳折衷。无法推荐具体的给药方案。既往有剖宫产史的患者发生子宫破裂的风险使得这些患者应使用最小有效剂量。在这种情况下,建议每次剂量不超过100μg。与在36至48小时前给予米非司酮联合使用时,引产-分娩时间和引产所需米索前列醇的剂量会减少。
米索前列醇在孕中期或孕晚期胎儿死亡或终止妊娠时引产有效且安全。